Clinical Mammalian

Manufacturing New Biologics, At Scale

GMP Drug Substance Manufacturing for FIH and Clinical Resupply Programs

 

After becoming the first CMO in the world to implement the 2000L scale Xcellerex™ single-use bioreactor at our Durham, NC, USA site, KBI Biopharma immediately began delivering GMP Drug Substance supplying FIH (First in Human) and clinical resupply programs.

In 2014, our proven track record for drug substance delivery facilitated manufacturing suite space expansion, adding another Seed Expansion, 500L→2000L bioreactor train, and purification suite.

In 2022, KBI expanded our clinical mammalian cGMP manufacturing capabilities within our site in Geneva, Switzerland, mirroring the Seed Expansion, 500L→2000L bioreactor train, and purification suite.

 

GMP Manufacturing for New Biologics

Our multi-product manufacturing facilities provide robust product segregation, pre-and post-viral downstream processing areas, and cross-contamination prevention.

The segregated HVAC design and personnel, material, and equipment flow together with the deployment of end-to-end single-use technology allow for maximum flexibility and rapid turn-around, all the while protecting your timelines and investment.

The mainstay of this success is our greatest asset - our team members. We are a diverse collection of experienced industry professionals, who understand the impact these new proteins, antibodies, and vaccines have on human health and put our hearts and experiences to work delivering outstanding quality products.

• 4x (500L→2000L) bioreactor train and purification suite
• Multiple trains with single-use (disposable) technology
• 24x7 manufacturing operations

Explore More Mammalian:

Ready to Learn More? Contact Us.